An Open Label Cryptosporidium Controlled Human Infection Model (CHIM) to Assess the Efficacy and Safety of ABO809 in Healthy Participants
Latest Information Update: 16 Jan 2023
At a glance
- Drugs KDU 731 (Primary)
- Indications Cryptosporidiosis
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 12 Jan 2023 Status changed from active, no longer recruiting to completed.
- 04 Nov 2022 Status changed from recruiting to active, no longer recruiting.
- 24 Oct 2022 Planned End Date changed from 13 Dec 2022 to 22 Dec 2022.